Literature DB >> 26992948

Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.

Silvia Salmoiraghi1, Marie Lorena Guinea Montalvo1, Greta Ubiali1, Manuela Tosi1, Barbara Peruta1, Pamela Zanghi1, Elena Oldani1, Cristina Boschini1, Alexander Kohlmann2, Silvia Bungaro3, Tamara Intermesoli1, Elisabetta Terruzzi4, Emanuele Angelucci5, Irene Cavattoni6, Fabio Ciceri7, Renato Bassan8, Alessandro Rambaldi9, Orietta Spinelli1.   

Abstract

Entities:  

Keywords:  TP53 mutations; acute lymphoblastic leukemia; early relapse; survival

Mesh：

Substances：

Year:  2016        PMID： 26992948      PMCID： PMC5013945          DOI： 10.3324/haematol.2015.137059

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

Review 1.  Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

Authors:  V H J van der Velden; A Hochhaus; G Cazzaniga; T Szczepanski; J Gabert; J J M van Dongen
Journal:  Leukemia       Date:  2003-06       Impact factor: 11.528

2.  Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

Authors:  Renato Bassan; Orietta Spinelli; Elena Oldani; Tamara Intermesoli; Manuela Tosi; Barbara Peruta; Giuseppe Rossi; Erika Borlenghi; Enrico M Pogliani; Elisabetta Terruzzi; Pietro Fabris; Vincenzo Cassibba; Giorgio Lambertenghi-Deliliers; Agostino Cortelezzi; Alberto Bosi; Giacomo Gianfaldoni; Fabio Ciceri; Massimo Bernardi; Andrea Gallamini; Daniele Mattei; Eros Di Bona; Claudio Romani; Anna Maria Scattolin; Tiziano Barbui; Alessandro Rambaldi
Journal:  Blood       Date:  2009-01-13       Impact factor: 22.113

Review 3.  Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

Authors:  M Brüggemann; A Schrauder; T Raff; H Pfeifer; M Dworzak; O G Ottmann; V Asnafi; A Baruchel; R Bassan; Y Benoit; A Biondi; H Cavé; H Dombret; A K Fielding; R Foà; N Gökbuget; A H Goldstone; N Goulden; G Henze; D Hoelzer; G E Janka-Schaub; E A Macintyre; R Pieters; A Rambaldi; J-M Ribera; K Schmiegelow; O Spinelli; J Stary; A von Stackelberg; M Kneba; M Schrappe; J J M van Dongen
Journal:  Leukemia       Date:  2009-12-24       Impact factor: 11.528

4.  TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.

Authors:  Sabina Chiaretti; Fulvia Brugnoletti; Simona Tavolaro; Silvia Bonina; Francesca Paoloni; Marilisa Marinelli; Nancy Patten; Massimiliano Bonifacio; Maria Grazia Kropp; Simona Sica; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2013-02-12       Impact factor: 9.941

5.  Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.

Authors:  Verena Mühlbacher; Melanie Zenger; Susanne Schnittger; Sandra Weissmann; Franziska Kunze; Alexander Kohlmann; Frauke Bellos; Wolfgang Kern; Torsten Haferlach; Claudia Haferlach
Journal:  Genes Chromosomes Cancer       Date:  2014-03-11       Impact factor: 5.006

6.  The IARC TP53 database: new online mutation analysis and recommendations to users.

Authors:  Magali Olivier; Ros Eeles; Monica Hollstein; Mohammed A Khan; Curtis C Harris; Pierre Hainaut
Journal:  Hum Mutat       Date:  2002-06       Impact factor: 4.878

7.  TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.

Authors:  Anna Stengel; Susanne Schnittger; Sandra Weissmann; Sabrina Kuznia; Wolfgang Kern; Alexander Kohlmann; Torsten Haferlach; Claudia Haferlach
Journal:  Blood       Date:  2014-05-14       Impact factor: 22.113

Review 8.  Pooled analysis of p53 mutations in hematological malignancies.

Authors:  M Prokocimer; R Unger; H S Rennert; V Rotter; G Rennert
Journal:  Hum Mutat       Date:  1998       Impact factor: 4.878
  8 in total
  12 in total

1.  The Expression of P53, MDM2, c-myc, and P14ARF Genes in Newly Diagnosed Acute Lymphoblastic Leukemia Patients.

Authors:  Mehdi Allahbakhshian Farsani; Mohammad Rafiee; Hamideh Aghaee Nezhad; Sina Salari; Arshia Gharehbaghian; Mohammad Hossein Mohammadi
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-16       Impact factor: 0.900

2.  TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.

Authors:  Rashmi Kanagal-Shamanna; Preetesh Jain; Koichi Takahashi; Nicholas J Short; Guilin Tang; Ghayas C Issa; Farhad Ravandi; Guillermo Garcia-Manero; Cameron C Yin; Rajyalakshmi Luthra; Keyur P Patel; Joseph D Khoury; Guillermo Montalban-Bravo; Koji Sasaki; Tapan M Kadia; Gautam Borthakur; Marina Konopleva; Nitin Jain; Rebecca Garris; Sherry Pierce; William Wierda; Zeev Estrov; Jorge Cortes; Susan O'Brien; Hagop M Kantarjian; Elias Jabbour
Journal:  Cancer       Date:  2017-06-13       Impact factor: 6.860

Review 3.  Germ line mutations associated with leukemias.

Authors:  Christopher C Porter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

4.  Genetic variants and clinical significance of pediatric acute lymphoblastic leukemia.

Authors:  Hong-Hong Zhang; Hong-Sheng Wang; Xiao-Wen Qian; Cui-Qing Fan; Jun Li; Hui Miao; Xiao-Hua Zhu; Yi Yu; Jian-Hua Meng; Ping Cao; Jun Le; Jun-Ye Jiang; Wen-Jing Jiang; Ping Wang; Xiao-Wen Zhai
Journal:  Ann Transl Med       Date:  2019-07

5.  Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT.

Authors:  Yiwen Wang; Weiyin Zhou; Junke Wang; Ezgi Karaesmen; Hancong Tang; Philip L McCarthy; Marcelo C Pasquini; Youjin Wang; Lisa J McReynolds; Hormuzd A Katki; Mitchell J Machiela; Meredith Yeager; Loreall Pooler; Xin Sheng; Christopher A Haiman; David Van Den Berg; Stephen R Spellman; Tao Wang; Michelle Kuxhausen; Stephen J Chanock; Stephanie J Lee; Alyssa I Clay-Gilmour; Theresa E Hahn; Shahinaz M Gadalla; Lara E Sucheston-Campbell
Journal:  Blood Adv       Date:  2021-01-12

6.  Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia.

Authors:  Maribel Forero-Castro; Cristina Robledo; Rocío Benito; Irene Bodega-Mayor; Inmaculada Rapado; María Hernández-Sánchez; María Abáigar; Jesús Maria Hernández-Sánchez; Miguel Quijada-Álamo; José María Sánchez-Pina; Mónica Sala-Valdés; Fernanda Araujo-Silva; Alexander Kohlmann; José Luis Fuster; Maryam Arefi; Natalia de Las Heras; Susana Riesco; Juan N Rodríguez; Lourdes Hermosín; Jordi Ribera; Mireia Camos Guijosa; Manuel Ramírez; Cristina Díaz de Heredia Rubio; Eva Barragán; Joaquín Martínez; José M Ribera; Elena Fernández-Ruiz; Jesús-María Hernández-Rivas
Journal:  Br J Cancer       Date:  2017-05-30       Impact factor: 7.640

7.  RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD.

Authors:  Ali Sakhdari; Beenu Thakral; Sanam Loghavi; Rashmi Kanagal-Shamanna; C Cameron Yin; Zhuang Zuo; Mark J Routbort; Rajyalakshmi Luthra; L Jeffrey Medeiros; Sa A Wang; Keyur P Patel; Chi Young Ok
Journal:  Cancer Med       Date:  2019-12-05       Impact factor: 4.452

8.  Immature Immunoglobulin Gene Rearrangements Are Recurrent in B Precursor Adult Acute Lymphoblastic Leukemia Carrying TP53 Molecular Alterations.

Authors:  Silvia Salmoiraghi; Roberta Cavagna; Marie Lorena Guinea Montalvo; Greta Ubiali; Manuela Tosi; Barbara Peruta; Tamara Intermesoli; Elena Oldani; Anna Salvi; Chiara Pavoni; Ursula Giussani; Renato Bassan; Alessandro Rambaldi; Orietta Spinelli
Journal:  Genes (Basel)       Date:  2020-08-20       Impact factor: 4.096

Review 9.  B lymphoblastic leukemia/lymphoma: new insights into genetics, molecular aberrations, subclassification and targeted therapy.

Authors:  Xiaohui Zhang; Prerna Rastogi; Bijal Shah; Ling Zhang
Journal:  Oncotarget       Date:  2017-07-15

10.  [Clinical and prognostic values of TP53 mutation in patients with B-lineage acute lymphoblastic leukemia].

Authors:  Y Y Du; K K Lyu; M M Xu; W Q Yao; H Z Kang; Y Han; X W Tang; X Ma; X J Wu; X F He; D P Wu; Y J Liu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2021-05-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.